SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-002172
Filing Date
2023-02-08
Accepted
2023-02-08 16:32:10
Documents
14
Period of Report
2023-02-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20230202.htm   iXBRL 8-K 58002
2 EX-10.1 sndx-ex10_1.htm EX-10.1 431408
3 EX-10.2 sndx-ex10_2.htm EX-10.2 87735
  Complete submission text file 0000950170-23-002172.txt   759365

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20230202_lab.xml EX-101.LAB 13916
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20230202.xsd EX-101.SCH 2463
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20230202_pre.xml EX-101.PRE 10229
8 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20230202_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 23599586
SIC: 2834 Pharmaceutical Preparations